bevacizumab,panitumumab
amgen,roche,takeda
['bevacizumab', 'panitumumab', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva']
#asco22 plenary panitumumab (pan) + mfolfox6 versus bevacizumab (bev) + mfolfox6 as 1st-line tx in pts w/ ras wt #metastatic #crcsm (mcrc): results from the ph 3 paradigm trial excellent discussion by dr. cremolini incl rationale for biologic differences l- vs r-sided crc. 
radiation oncologist @MSKCancerCenter | #bcsm + #metastatic dz | #HSR #impsci | visiting scholar @PC3Innovation | #PeloASTRO ?? ?